Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area
- PMID: 16856208
- DOI: 10.1002/eji.200636187
Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area
Abstract
A heterologous prime-boost strategy has been developed to potently induce T cell responses to pre-erythrocytic malaria antigens. Efficacy in the field is likely to depend on both peak immunogenicity and the durability of responses. To improve both immunogenicity and durability of responses, 54 adult males from a malaria endemic area were immunized with different vaccination regimens, systematically varying antigenic insert and the number and sequence of component vaccinations. The component vaccinations were recombinant attenuated viruses, either fowlpox (FP) 9 or modified vaccinia virus Ankara (MVA). These were recombinant for either of two pre-erythrocytic malaria antigens (multiple epitope-thrombospondin-related adhesion protein, ME-TRAP, or circumsporozoite antigen (CS). ELISPOT assays were used to measure the effector and resting memory T cell responses. Sequence, antigen insert and number of vaccinations influenced immunogenicity, but the novel alternating vector immunizations generated the largest resting memory T cell populations. Effector responses were maintained at 84% of the peak response after 270 days. This durability of response is unprecedented. Classical prime-boost vaccination responses were at 5% of the peak after 270 days. Vaccines administered by heterologous prime-boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development.
Similar articles
-
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.Clin Infect Dis. 2006 Apr 15;42(8):1102-10. doi: 10.1086/501459. Epub 2006 Mar 14. Clin Infect Dis. 2006. PMID: 16575727
-
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24. J Infect Dis. 2004. PMID: 15181568 Clinical Trial.
-
Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.Vaccine. 2006 May 29;24(22):4709-15. doi: 10.1016/j.vaccine.2006.03.029. Epub 2006 Mar 31. Vaccine. 2006. PMID: 16621181 Clinical Trial.
-
Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Immunol Rev. 2004 Jun;199:126-43. doi: 10.1111/j.0105-2896.2004.00138.x. Immunol Rev. 2004. PMID: 15233731 Review.
-
Predicting memory: a prospective readout for malaria vaccines?Trends Parasitol. 2007 Aug;23(8):341-3. doi: 10.1016/j.pt.2007.06.006. Epub 2007 Jun 22. Trends Parasitol. 2007. PMID: 17586093 Review.
Cited by
-
The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.J Immunol. 2007 Sep 15;179(6):4193-201. doi: 10.4049/jimmunol.179.6.4193. J Immunol. 2007. PMID: 17785859 Free PMC article. Clinical Trial.
-
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7. Vaccine. 2011. PMID: 21216311 Free PMC article. Clinical Trial.
-
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16. Mol Ther. 2014. PMID: 24930599 Free PMC article. Clinical Trial.
-
A review of malaria vaccine clinical projects based on the WHO rainbow table.Malar J. 2012 Jan 9;11:11. doi: 10.1186/1475-2875-11-11. Malar J. 2012. PMID: 22230255 Free PMC article. Review.
-
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.PLoS Clin Trials. 2006 Oct 20;1(6):e29. doi: 10.1371/journal.pctr.0010029. PLoS Clin Trials. 2006. PMID: 17053830 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical